Pure Biologics

Pure Biologics Equity Growth

The Year-over-Year Equity Growth of Pure Biologics (PUR.WA) as of Nov 12, 2026 is -7.86 %. In the previous year, Year-over-Year Equity Growth was -792.87 % — a change of -99.01% (higher).

Equity Growth

-7.86 %

YoY

-99.01%

Last updated:

Year-over-Year Equity Growth of Pure Biologics is 2025 -7.86 % . Year-over-Year Equity Growth of Pure Biologics was 2024 -792.87 % . It decreases by -99.01% higher compared to the previous year.

The Pure Biologics Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2018
958.71 PLN
Jan 1, 2019
224.80 PLN
Jan 1, 2020
-140.02 PLN
Jan 1, 2021
1,467.72 PLN
Jan 1, 2022
-53.66 PLN
Jan 1, 2023
-89.65 PLN
Jan 1, 2024
-792.87 PLN
Jan 1, 2025
-7.86 PLN
The Pure Biologics Equity Growth history
YEAREquity GrowthYoY
-7.86 %-99.01%
-792.87 %+784.36%
-89.65 %+67.07%
-53.66 %-103.66%
1,467.72 %-1,148.20%
-140.02 %-162.29%
224.80 %-76.55%
958.71 %-3,031.88%
-32.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Pure Biologics Stock analysis

What does Pure Biologics do? Pure Biologics SA, headquartered in Wrocław, Poland, operates in the Health Care sector as a biotechnology company. It focuses on research and development of innovative biological medicines and medical devices for therapeutic and diagnostic applications. The company employs 53 full-time staff and was listed on the stock market on 11 December 2018. Founded in August 2010, it remains based in Wrocław, focusing on biopharmaceutical solutions. Pure Biologics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pure Biologics stock

Year-over-Year Equity Growth of Pure Biologics is -7.86 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth Pure Biologics since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's Pure Biologics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Pure Biologics

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Pure Biologics